New drugs for familiar therapeutic targets: Thrombopoietin receptor agonists and immune thrombocytopenic purpura

European Journal of Haematology

Volumn 80, Issue SUPPL. 69, 2008, Pages 9-18

  Kuter, David J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Idiopathic; Megakaryocytes; Platelet count; Purpura; Thrombocytopenic; Thrombopoiesis; Thrombopoietin

Indexed keywords

5 OXO 1,5 DIHYDROPYRAZOL 4 YLIDENE HYDRAZINE; AKR 501; ANTINEOPLASTIC AGENT; ELTROMBOPAG; FAB 59; MONOCLONAL ANTIBODY MA01G4G344; MONOCLONAL ANTIBODY VB22B; PEGINTERFERON; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; POLYETHYLENE GLYCOL THROMBOPOIETIN MIMETIC PEPTIDE; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; RETICULIN; RIBAVIRIN; RITUXIMAB; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG; YM 477; BENZOIC ACID DERIVATIVE; CARRIER PROTEIN; FC RECEPTOR; HYDRAZINE DERIVATIVE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; POLYETHYLENE GLYCOL RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; POLYETHYLENE GLYCOL-RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PYRAZOLE DERIVATIVE; RECOMBINANT PROTEIN;

ANTIGENICITY; ARTICLE; BLEEDING; CHROMOSOME ABERRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROSIS; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT OUTCOME; VOMITING; XEROSTOMIA; CHEMISTRY; DRUG ANTAGONISM; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; REVIEW; THROMBOCYTE;

ANTIBODIES, MONOCLONAL; BENZOIC ACIDS; BLOOD PLATELETS; CARRIER PROTEINS; HUMANS; HYDRAZINES; POLYETHYLENE GLYCOLS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT PROTEINS; THROMBOPOIESIS; THROMBOPOIETIN;

EID: 38649127253     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00999.x     Document Type: Article

References (69)

1. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994 77 : 1117 24.
2. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994 91 : 11104 8.
3. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994 369 : 565 8.
4. de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994 369 : 533 8.
5. Kato T, Ogami K, Shimada Y, et al. Purification and characterization of thrombopoietin. J Biochem (Tokyo) 1995 118 : 229 36.
6. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002 99 : 2599 602.
7. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98 : 3241 8.
8. Kuter DJ. New thrombopoietic growth factors. Blood 2007 109 : 4607 16.
9. Linden HM, Kaushansky K. The glycan domain of thrombopoietin enhances its secretion. Biochemistry 2000 39 : 3044 51.
10. Muto T, Feese MD, Shimada Y, et al. Functional analysis of the C-terminal region of recombinant human thrombopoietin. C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion. J Biol Chem 2000 275 : 12090 4.
11. Solar GP, Kerr WG, Zeigler FC, et al. Role of c-Mpl in early hematopoiesis. Blood 1998 92 : 4 10.
12. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995 85 : 391 401.
13. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA 1995 92 : 5292 6.
14. Miyakawa Y, Oda A, Druker BJ, et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of janus kinase 2 and Shc in human blood platelets. Blood 1995 86 : 23 7.
15. Sattler M, Durstin MA, Frank DA, et al. The thrombopoietin receptor c-Mpl activates Jak2 and Tyk2 tyrosine kinases. Exp Hematol 1995 23 : 1040 8.
16. Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol 1997 17 : 4991 5000.
17. Matsumura I, Nakajima K, Wakao H, et al. Involvement of prolonged Ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line. Mol Cell Biol 1998 18 : 4282 90.
18. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 2004 101 : 1816 21.
19. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999 94 : 365 7.
20. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999 283 : 990 3.
21. Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999 283 : 987 90.
22. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996 87 : 567 73.
23. Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998 92 : 2189 91.
24. Siemensma NP, Bathal PS, Penington DG. The effect of massive liver resection on platelet kinetics in the rat. J Lab Clin Med 1975 86 : 817 33.
25. Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997 27 : 127 31.
26. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60D 6D.
27. Yang C, Li J, Kuter DJ. The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999 105 : 478 85.
28. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997 89 : 1896 904.
29. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-Mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999 106 : 345 56.
30. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-Mpl-mediated binding to platelets. Blood 1996 87 : 2154 61.
31. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997 89 : 2782 8.
32. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994 84 : 1464 72.
33. Nichol JL. Serum levels of thrombopoietin in health and disease. In : Kuter DJ, Hunt P, Sheridan W, Zucker-Franklin D, eds. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Totowa, NJ : Humana Press Inc, 1996 : 359 75.
34. Kuter DJ. The physiology of platelet production. Stem Cells 1996 14 (Suppl. 1 88 101.
35. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997 126 : 673 81.
36. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000 132 : 364 8.
37. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001 98 : 1339 45.
38. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002 100 : 728 30.
39. Kuter DJ. Future directions with platelet growth factors. Semin Hematol 2000 37 : 41 9.
40. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997 276 : 1696 9.
41. Frederickson S, Renshaw MW, Lin B, et al. A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA 2006 103 : 14307 12.
42. Cerneus D, Brown K, Harris R, et al. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist. Blood (ASH Annual Meeting Abstracts) 2005 106 : 1249.
43. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004 25 : 52 60.
44. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004 76 : 628 38.
45. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006 355 : 1672 81.
46. Kuter D, Bussel J, George J, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood (ASH Annual Meeting Abstracts) 2006 108 : 476.
47. Kantarjian HM, Giles FJ, Fenaux P, et al. Evaluating safety and efficacy of AMG 531 for the treatment of thrombocytopenic patients with myelodysplastic syndrome (MDS): preliminary results of a phase 1/2 study. J Clin Oncol (Meeting Abstracts) 2007 25 : 7032.
48. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J Med Chem 2001 44 : 3730 45.
49. Suzuki K-i, Abe M, Fukushima-Shintani M, et al. YM477, a novel orally-active thrombopoietin receptor agonist. Blood (ASH Annual Meeting Abstracts) 2005 106 : 2298.
50. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood (ASH Annual Meeting Abstracts) 2006 108 : 477.
51. US Pharmacopeia. USP Dictionary of USAN and International Drug Names 2005. Dictionary Supplement 5.
52. Luengo JI, Duffy KJ, Shaw AN, et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood (ASH Annual Meeting Abstracts) 2004 104 : 2910.
53. Erickson-Miller C, Delorme E, Giampa L, et al. Biological activity and selectivity for TPO receptor of the orally bioavailable, small molecule TPO receptor agonist, SB-497115. Blood (ASH Annual Meeting Abstracts) 2004 104 : 2912.
54. Erickson-Miller CL, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood (ASH Annual Meeting Abstracts) 2004 104 : 2909.
55. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-Gr, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood (ASH Annual Meeting Abstracts) 2004 104 : 3888.
56. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007 109 : 4739 41.
57. Bussel JB, Provan A, Shamsi T, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 357 : 2237 47.
58. Bussel JB, Provan A, Shamsi T, et al. Eltrombopag Raises Platelet Count and Reduces Bleeding Compared With Placebo During Short-Term Treatment in Chronic Idiopathic Thrombocytopenic Purpura: A Phase III Study. 12th Congress of the European Hematology Association June 7-10, 2007; Vienna, Austria Abstract 0390 2007.
59. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007 357 : 2227 36.
60. Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005 105 : 562 6.
61. Kai M, Motoki K, Yoshida H, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. Blood (ASH Annual Meeting Abstracts) 2006 108 : 1134.
62. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997 336 : 404 9.
63. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000 18 : 2852 61.
64. Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996 88 : 511 21.
65. Peng J, Friese P, Wolf RF, et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996 87 : 4158 63.
66. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007 139 : 351 62.
67. Ulich TR, del Castillo J, Senaldi G, et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996 87 : 5006 15.
68. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 1997 99 : 739 45.
69. Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002 117 : 844 50.